Kadance

Executive Summary

Kadance is a US-based biotechnology company pioneering novel cell therapies for solid tumors. The company's proprietary platform engineers T cells with enhanced tumor-homing and persistence capabilities, aiming to overcome the immunosuppressive tumor microenvironment that limits current immunotherapies. Its lead programs target aggressive cancers with high unmet need, leveraging differentiated mechanisms to improve efficacy and durability of response. Kadance's approach addresses key challenges in solid tumor cell therapy, positioning it as a potential leader in the next wave of adoptive cell therapies. Kadance is currently in Phase 2 clinical development, with ongoing trials evaluating its lead candidate in multiple solid tumor indications. The company has demonstrated promising early safety and efficacy signals, supporting advancement into later-stage studies. With a strong scientific foundation and a focused pipeline, Kadance is well-positioned to deliver transformative treatments for patients with hard-to-treat cancers. The company's progress and strategic execution will be critical determinants of its success in the competitive cell therapy landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim efficacy data readout for lead program70% success
• Q4 2026Strategic partnership or licensing deal for co-development or commercialization50% success